SirPAD Trial Results Signal New Era for Peripheral Artery Disease Treatment

TAMPA, FL – March 31, 2026 – A landmark clinical trial has delivered compelling evidence for a new generation of treatment for Peripheral Artery Disease (PAD), a debilitating condition affecting over 200 million people worldwide. The results, presented as a late-breaking presentation at the American College of Cardiology's 2026 Scientific Sessions and simultaneously published in the New England Journal of Medicine, show that a sirolimus-coated balloon developed by Concept Medical Inc. significantly reduces the risk of major amputations and repeat procedures compared to the current standard of care.

The trial, known as SirPAD, is the largest randomized controlled study of its kind. Its findings position the MagicTouch PTA sirolimus-coated balloon as a powerful new tool for physicians and a source of hope for patients suffering from narrowed arteries in their limbs, a condition that can lead to severe pain, non-healing wounds, and limb loss.

A Breakthrough for a Pervasive Disease

Peripheral Artery Disease is a common circulatory problem where plaque buildup narrows the arteries, reducing blood flow, primarily to the legs. While some individuals are asymptomatic, many experience claudication—pain and cramping during physical activity. In its most severe forms, known as critical limb ischemia (CLI), the lack of blood flow causes pain even at rest and can lead to gangrene, making it a leading cause of non-traumatic amputations.

For decades, the primary interventional treatment has been plain balloon angioplasty, where a small balloon is inflated inside the artery to compress the plaque. However, this method is plagued by high rates of restenosis, or re-narrowing of the artery, often occurring in up to 50% of patients within a year. While stents and other devices have offered improvements, the search for a more durable and safer solution has been a central goal in vascular medicine.

Drug-coated balloons (DCBs) emerged as a promising advancement, designed to deliver an anti-proliferative drug directly to the vessel wall to prevent the scar tissue growth that causes restenosis. The SirPAD trial provides the most robust evidence to date for the efficacy of a sirolimus-based approach in this challenging patient population.

Unpacking the 'Game-Changing' SirPAD Data

The academic, investigator-led SirPAD trial enrolled 1,252 patients with PAD affecting the arteries in the thigh (femoropopliteal) or below the knee. Patients were randomly assigned to receive treatment with either the MagicTouch PTA sirolimus-coated balloon or a standard uncoated balloon angioplasty.

The results at one year were striking. The primary outcome—a composite of major adverse limb events (MALE) including major unplanned amputations or the need for repeat procedures due to critical ischemia—occurred in just 8.8% of patients treated with the sirolimus balloon. This was a dramatic reduction compared to the 15% rate seen in the group receiving standard angioplasty. The data demonstrated both noninferiority and clear superiority in favor of the MagicTouch PTA device.

A key strength of the study, and a reason for the excitement in the medical community, is its "all-comers" design. Unlike many clinical trials that have strict exclusion criteria, SirPAD enrolled consecutive, real-world patients, regardless of the complexity of their arterial blockages or the stage of their disease. Crucially, nearly half of the participants presented with acute or chronic limb-threatening ischemia, the most advanced and difficult-to-treat form of PAD.

"We are excited about the primary outcome results of SirPAD," said Principal Investigators Prof. Dr. med. Nils Kucher and Prof. Dr. med. Stefano Barco, who co-chaired the trial, following the presentation. "It is one of the very few trials in this field that successfully included an all-comers population... thereby providing enough events and statistical power to demonstrate superiority for hard clinical outcomes at one year."

A Market Shift: The Rise of Sirolimus

The success of a sirolimus-coated balloon comes at a pivotal moment for the vascular device market. For years, the dominant drug used on DCBs was paclitaxel. However, the market was unsettled by a 2018 meta-analysis that suggested a potential long-term mortality risk, leading to an FDA warning and a significant drop in use. Although extensive subsequent reviews, including patient-level data from multiple large studies, led the FDA to officially reverse its warning in 2023, the episode created an urgent demand for proven alternatives.

Sirolimus, which has a long track record of safety and efficacy in coronary drug-eluting stents, works through a different biological pathway than paclitaxel. It is cytostatic, meaning it inhibits cell proliferation, rather than cytotoxic. Concept Medical's proprietary Nanolute Technology is designed to deliver the drug effectively into the vessel wall for a sustained therapeutic effect.

The SirPAD results build upon previous evidence from the SIRONA trial, which demonstrated that MagicTouch PTA was non-inferior to a range of commercially available paclitaxel-coated balloons in treating femoropopliteal artery disease. Together, these two major trials create a powerful body of evidence: MagicTouch PTA is as effective as its paclitaxel counterparts and vastly superior to uncoated balloons, offering a robust alternative without the baggage of past controversies.

Implications for Patients, Physicians, and the Industry

The SirPAD data is poised to have a ripple effect across the healthcare landscape. For physicians treating PAD, it provides Level 1 evidence—the highest standard—supporting a new and highly effective treatment option. The trial's real-world population gives clinicians confidence that the results are applicable to the diverse and often complex patients they see every day.

"SirPAD is an important milestone for the PAD community and for the continued evolution of sirolimus-coated balloon therapy," said Dr. Manish Doshi, Founder and Managing Director of Concept Medical. "Seeing MagicTouch PTA evaluated in a large, investigator-led randomized trial and supported by peer-reviewed publication reinforces our belief that meaningful innovation must be validated through rigorous science."

This validation is expected to significantly impact the competitive landscape, currently dominated by major players like Boston Scientific and Medtronic with their paclitaxel-based devices. With CE mark approval in Europe and multiple Investigational Device Exemptions (IDEs) from the FDA to conduct pivotal trials in the United States, Concept Medical is on a clear path to challenge the market status quo. The strength of the SirPAD data will be instrumental in its pursuit of full FDA approval and favorable reimbursement decisions.

Ultimately, the findings may influence a fundamental revision of clinical practice guidelines for treating Peripheral Artery Disease, potentially establishing sirolimus-coated balloons as a new standard of care and offering millions of patients a better chance at saving their limbs and improving their quality of life.